GERN Earnings – Q2 2026
Geron Corporation (Nasdaq: GERN) reported second-quarter results on August 5, 2026, showing continued commercial progress for its telomerase inhibitor RYTELO […]
gene-therapy
PGEN Earnings – Q2 2026
Precigen, Inc. (Nasdaq: PGEN) reported transformative second-quarter results on August 4, 2026, driven by accelerating commercial sales of PAPZIMEOS, its
Geron Corp. (GERN)
Geron Corp. (NASDAQ: GERN) is a commercial-stage biopharmaceutical company dedicated to changing the lives of patients by changing the course of
PGEN Earnings – Q4 2025
Precigen, Inc. (NASDAQ: PGEN) released its Q4 and full-year 2025 results on March 25, 2026. The narrative is shifting from
Precigen Inc. (PGEN)
Precigen Inc. (NASDAQ: PGEN) is a biopharmaceutical company that focuses on advancing the next generation of gene and cell therapies
